Patents by Inventor Diane E. Peters

Diane E. Peters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD)
    Publication number: 20230128984
    Abstract: GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 27, 2023
    Inventors: Barbara Slusher, Diane E. Peters, Rana Rais, Pavel Majer, Lukas Tenora, Ivan Snajdr
  • Modified anthrax toxin protective antigen
    Patent number: 10835593
    Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Assignee: The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Shi-Hui Liu, Stephen H. Leppla, Thomas H. Bugge, Alexander N. Wein, Diane E. Peters, Jie Liu, Kuang-Hua Chen
  • MODIFIED ANTHRAX TOXIN PROTECTIVE ANTIGEN
    Publication number: 20180250376
    Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Application
    Filed: August 25, 2016
    Publication date: September 6, 2018
    Applicant: The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Shi-Hui Liu, Stephen H. Leppla, Thomas H. Bugge, Alexander N. Wein, Diane E. Peters, Jie Liu, Kuang-Hua Chen